БИФИДОГЕННЫЕ СВОЙСТВА БИОТЕХНОЛОГИЧЕСКОГО АНАЛОГА ЛАКТОФЕРРИНА ЧЕЛОВЕКА

Background:  Recent research shows that the growth and development of the gastrointestinal  tract of children fed by breast milk is more intense than that of the formula fed, since the human lactoferrin contained in the breast milk is a factor that stimulates cell growth. Therefore, the possibility of using exogenous lactoferrin will be of great importance in the nutrition of infants.Objektive: To study the bifidogenic properties of the biotechnological analogue of human lactoferrin. Methods: Kinetics of growth and CFU titer of bifidobacterial culture in the presence of a biotechnological analogue of human lactoferrin (0,05–5 mg /ml) was determined.Results: It has been shown that different concentrations of the protein can have both a stimulating (for B. bifidum and B. infantis) and inhibitory (for B. longum) effect on the growth of bifidobacteria, which is due to the affinity of lactoferrin binding to them. It seems important to further study the stimulating effect of this protein on the growth of lactobacilli in the intestine of the child.Conclusion:  Due to bifidogenic and high bactericidal action, lactoferrin can be effective in feeding newborns.Обоснование.   Новейшие исследования  показывают,  что  рост  и развитие  желудочно-кишечного  тракта  детей, вскармливаемых  материнским молоком,  происходит  интенсивнее,  чем у вскармливаемых  молочными смесями, поскольку содержащийся в нем лактоферрин человека является фактором, стимулирующим клеточный рост. Именно поэтому возможность  использования экзогенного лактоферрина  будет иметь большую значимость в питании грудных детей.Цель  исследования — изучить бифидогенные  свойства биотехнологического аналога  лактоферрина человека.Методы. Определялась кинетика роста и КОЕ-титр культивирования бифидобактерий в присутствии биотехнологического  аналога лактоферрина человека.Результаты. Показано, что различные концентрации данного белка (0,05–5 мг/мл) могут оказывать как стимулирующее (для Bifidobacterium bifidum и Bifidobacterium infantis), так и ингибирующее (для Bifidobacterium longum) действие в отношении роста бифидобактерий,  что обусловлено аффинностью  связывания с ними лактоферрина. Представляется  важным дальнейшее изучение стимулирующего эффекта  этого белка на рост лактобацилл в кишечнике ребенка.Заключение. Благодаря  бифидогенному и выраженному бактерицидному действию лактоферрин может быть использован в лечебном питании новорожденных

BIFIDOGENIC PROPERTIES OF A BIOTECHNOLOGICAL ANALOGUE OF HUMAN LACTOFERRIN

Background:  Recent research shows that the growth and development of the gastrointestinal  tract of children fed by breast milk is more intense than that of the formula fed, since the human lactoferrin contained in the breast milk is a factor that stimulates cell growth. Therefore, the possibility of using exogenous lactoferrin will be of great importance in the nutrition of infants.Objektive: To study the bifidogenic properties of the biotechnological analogue of human lactoferrin. Methods: Kinetics of growth and CFU titer of bifidobacterial culture in the presence of a biotechnological analogue of human lactoferrin (0,05–5 mg /ml) was determined.Results: It has been shown that different concentrations of the protein can have both a stimulating (for B. bifidum and B. infantis) and inhibitory (for B. longum) effect on the growth of bifidobacteria, which is due to the affinity of lactoferrin binding to them. It seems important to further study the stimulating effect of this protein on the growth of lactobacilli in the intestine of the child.Conclusion:  Due to bifidogenic and high bactericidal action, lactoferrin can be effective in feeding newborns

EFFICIENCY OF USING THE ADAPTED GOAT’S MILK FORMULA IN THE DIET OF HEALTHY YOUNG INFANTS: A MULTICENTER PROSPECTIVE COMPARATIVE STUDY

Background. There is no doubt that it is necessary to study the efficiency of milk formulas that are introduced into the Russian market of baby food. This applies to both new products and known brands of formulas whose composition is subject to change.Objective. Our aim was to assess the clinical efficacy of the adapted goat's milk formula in the diet of young infants.Methods. We conducted a prospective comparative study with healthy full-term  children aged 0–5 months being on a formula (main group) or breast feeding (comparison group). The tolerability of the adapted goat's milk formula, the dynamics of anthropometric indicators, changes in body composition as well as microscopic characteristics  of stool and general clinical and biochemical parameters  of peripheral blood were assessed after 1 month.Results. Good tolerability of the goat's milk formula was noted in 184 (96.8%) of 190 children in the main group. In the course of taking the product, the proportion of children with functional disorders of the gastrointestinal tract decreased significantly from 57 (30%) to 27 (14%) (p < 0.001). Physical development,  complete blood count results, the levels of ferritin, prealbumin and 25(OH)D in children of the main group and the comparison group (n = 71) were comparable and were within the mean age parameters. Qualitative analysis of the level of specific IgE to goat's milk proteins did not reveal any sensibilization in any of the children receiving the milk formula, either at the beginning of the study or after 1 month of taking the product.Conclusion. The studied adapted goat's milk formula can be used in nutrition of young infants in cases of lack or absence of mother's milk